Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed Or Refractory Non-Hodgkin Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)Study completedNCT01909934
What this trial is testing

Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Who this might be right for
Lymphoma
Takeda 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT03598998
What this trial is testing

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

Who this might be right for
Anaplastic Large Cell LymphomaNodal Peripheral T-Cell Lymphoma With TFH PhenotypeRecurrent Anaplastic Large Cell Lymphoma+17 more
City of Hope Medical Center 13
Testing effectiveness (Phase 2)Study completedNCT02401048
What this trial is testing

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas

Who this might be right for
Diffuse Large B-Cell LymphomaFollicular Lymphoma
Pharmacyclics LLC. 61
Not applicableLooking for participantsNCT05846763
What this trial is testing

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study

Who this might be right for
Follicular Lymphoma
Institute of Hematology & Blood Diseases Hospital, China 50
Early research (Phase 1)Temporarily pausedNCT00077493
What this trial is testing

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
MedImmune LLC 95
Very early researchLooking for participantsNCT04512716
What this trial is testing

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Who this might be right for
B-ALLDLBCLB ALL+8 more
Memorial Sloan Kettering Cancer Center 12
Early research (Phase 1)Active Not RecruitingNCT04606433
What this trial is testing

Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Who this might be right for
Non Hodgkin LymphomaAcute Lymphoblastic Leukemia
Sichuan Baili Pharmaceutical Co., Ltd. 47
Testing effectiveness (Phase 2)Study completedNCT02445248
What this trial is testing

Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients

Who this might be right for
Diffuse Large B-cell Lymphoma (DLBCL)
Novartis Pharmaceuticals 115
Testing effectiveness (Phase 2)UnknownNCT01678404
What this trial is testing

131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma

Who this might be right for
Relapsed or Refractory Marginal Zone B-cell Lymphoma
Korea Cancer Center Hospital 28
Testing effectiveness (Phase 2)Study completedNCT03235544
What this trial is testing

INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor

Who this might be right for
Lymphoma
Incyte Corporation 162
Early research (Phase 1)Looking for participantsNCT05967416
What this trial is testing

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Refractory Non-Hodgkin LymphomaRelapsed Non-Hodgkin Lymphoma
SIRPant Immunotherapeutics, Inc. 24
Early research (Phase 1)Looking for participantsNCT06980116
What this trial is testing

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Relapsed or Refractory B-cell MalignanciesChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Follicular Lymphoma (FL)+4 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. 85
Large-scale testing (Phase 3)Active Not RecruitingNCT04384484
What this trial is testing

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Relapsed Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
ADC Therapeutics S.A. 440
Testing effectiveness (Phase 2)Active Not RecruitingNCT04054167
What this trial is testing

Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Who this might be right for
Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center 51
Testing effectiveness (Phase 2)WithdrawnNCT02285244
What this trial is testing

Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation

Who this might be right for
Prolymphocytic LeukemiaRecurrent Mantle Cell LymphomaRecurrent Small Lymphocytic Lymphoma+2 more
James Blachly
Testing effectiveness (Phase 2)Study completedNCT01466881
What this trial is testing

Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

Who this might be right for
Adult Nasal Type Extranodal NK/T-Cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-Cell Lymphoma+4 more
National Cancer Institute (NCI) 42
Testing effectiveness (Phase 2)Ended earlyNCT03578198
What this trial is testing

Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)

Who this might be right for
CD20-positive Non-Hodgkin Lymphoma
Seoul National University Hospital 12
Testing effectiveness (Phase 2)Study completedNCT00867529
What this trial is testing

Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma

Who this might be right for
B-cell Adult Acute Lymphoblastic LeukemiaB-cell Childhood Acute Lymphoblastic LeukemiaB-cell Chronic Lymphocytic Leukemia+35 more
Fred Hutchinson Cancer Center 63
Early research (Phase 1)Study completedNCT02595866
What this trial is testing

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

Who this might be right for
AIDS-Related Non-Hodgkin LymphomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+16 more
National Cancer Institute (NCI) 58
Large-scale testing (Phase 3)Study completedNCT03575351
What this trial is testing

Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

Who this might be right for
Lymphoma, Non-Hodgkin
Celgene 184
Next Page